title: Bone health and vitamin D status in alcoholic liver disease.
abstract: Alcohol consumption is harmful to many organs and tissues, including bones, and it leads to osteoporosis. Hepatic osteodystrophy is abnormal bone metabolism that has been defined in patients with chronic liver disease (CLD), including osteopenia, osteoporosis, and osteomalacia. Decreased bone density in patients with CLD results from decreased bone formation or increased bone resorption. The prevalence of osteopenia in alcoholic liver disease (ALD) patients is between 34 % and 48 %, and the prevalence of osteoporosis is between 11 % and 36 %. Cirrhosis is also a risk factor for osteoporosis. The liver has an important role in vitamin D metabolism. Ninety percent of patients with alcoholic liver cirrhosis have vitamin D inadequacy (<80 nmol/L). The lowest serum vitamin D levels were observed in patients with Child-Pugh class C. Bone densitometry is used for the definitive diagnosis of osteoporosis in ALD. There are no specific controlled clinical studies on the treatment of osteoporosis in patients with ALD. Alcohol cessation and abstinence are principal for the prevention and treatment of osteoporosis in ALD patients, and the progression of osteopenia can be stopped in this way. Calcium and vitamin D supplementation is recommended, and associated nutritional deficiencies should also be corrected. The treatment recommendations of osteoporosis in CLD tend to be extended to ALD. Bisphosphonates have been proven to be effective in increasing bone mineral density (BMD) in chronic cholestatic disease and post-transplant patients, and they can be used in ALD patients. Randomized studies assessing the management of CLD-associated osteoporosis and the development of new drugs for osteoporosis may change the future. Here, we will discuss bone quality, vitamin D status, mechanism of bone effects, and diagnosis and treatment of osteoporosis in ALD.
authors.affiliation: Department of Endocrinology and Metabolism, Diskapi Teaching and Research Hospital, Ankara, Turkey. muhammedkzgl@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Kizilgul
authors.affiliation: Department of Endocrinology and Metabolism, Diskapi Teaching and Research Hospital, Ankara, Turkey.
authors.forename: O
authors.initials: O
authors.lastname: Ozcelik
authors.affiliation: Department of Endocrinology and Metabolism, Diskapi Teaching and Research Hospital, Ankara, Turkey.
authors.forename: T
authors.initials: T
authors.lastname: Delibasi
mesh_terms: D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D055808:Drug Discovery; D006801:Humans; D008099:Liver / Q000378:metabolism; D008108:Liver Diseases, Alcoholic / Q000150:complications* / Q000378:metabolism*; D010024:Osteoporosis / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism* / Q000628:therapy; D014807:Vitamin D / Q000378:metabolism*; D014808:Vitamin D Deficiency / Q000209:etiology*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D014807:Vitamin D
keywords: Alcoholic liver disease; Bone; Bone mineral density; Osteoporosis; Vitamin D